Is SABR cost-effective in oligometastatic cancer? An economic analysis of SABR-COMET randomized trial

The phase II randomized study SABR-COMET demonstrated that in cancer patients with 1-5 oligometastatic lesions, stereotactic ablative radiotherapy (SABR) was associated with an improvement in both progression-free survival and overall survival compared to standard of care (SoC). SABR, however, is associated with higher costs and treatment-related toxicity. The objective of this study was to assess the cost-effectiveness of SABR versus SoC in patients with oligometastatic disease. A time-dependent Markov model with five health states was constructed from the Canadian health care system perspective. Utility values and transition probabilities were derived from the SABR-COMET trial. Costs were obtained from the published literature. A willingness-to-pay threshold of $100,000/quality adjusted life year (QALY) was used. SABR was cost-effective in the base case, at an incremental cost-effectiveness ratio of $37,157/ QALY gained over a lifetime horizon, as compared to the SoC. Therefore, administering SABR is cost-effective for patients with 1-5 oligometastatic lesions compared to SoC.

Name thesis:degree_name

M Sc

Discipline thesis:degree_discipline

Epidemiology and Biostatistics

Grantor dc:publisher

The University of Western Ontario

Year dc:date.issued

2019

Author dc:creator

• Chen, Yujie

Advisors dc:contributor.advisor

• Louie, Alexander
• Zaric, Greg

• cost-effectiveness
• stereotactic ablative radiotherapy (SABR)
• oligometastases

Language dc:language.iso

en_ca

Handle dc:identifier.uri

https://hdl.handle.net/20.500.14721/29760

OAI identifier oai:identifier

oai:uwo.scholaris.ca:20.500.14721/29760